相关实验视频
Updated: Jul 1, 2026

08:49
External Cephalic Version: Is it an Effective and Safe Procedure?
Published on: June 6, 2020
14.6K
诱导肥胖妇女分娩的方法:对两个多中心随机对照试验的二次分析
Dorothée M R Croll1, Marieke D T De Vaan2,3, Shinta L Moes1
1Department of Obstetrics, Division Woman and Baby, Wilhelmina Children's Hospital Birth Center, University Medical Center Utrecht, Utrecht, the Netherlands.
Acta obstetricia et gynecologica Scandinavica
|January 6, 2024
概括
在肥胖的孕妇中,福利导管诱导显示了与mizoprostol或prostaglandin E2相比,更多的剖腹产和失败安置的更高风险的趋势. 这些发现有助于共享劳动诱导方法的决策.
科学领域:
- 产科和妇科 产科和妇科
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 生殖健康 生殖健康
背景情况:
- 肥胖是一个日益严重的全球健康问题,增加了怀孕和分娩并发症.
- 患有肥胖症的女性经常需要出于各种医疗原因诱导分娩.
- 确定肥胖女性最安全,最有效的诱导方法至关重要.
研究的目的:
- 为了比较不同劳动诱导方法在肥胖妇女的安全性和有效性.
- 评估接受诱导的肥胖妇女的剖腹产率和产后出血.
- 评估福利导管安置在肥胖女性与非肥胖女性中的成功率.
主要方法:
- 两项随机对照试验 (PROBAAT-I和PROBAAT-II) 的二次分析.
- 纳入标准:单期单胎妊娠,头部表现,不良的子宫,完整的膜,没有先前的剖腹产.
- 福利导管,阴道前列腺素E2-凝和口服美索普罗斯托尔的比较,用于在体重指数≥30.0.的女性中诱导分娩.
主要成果:
- 福利导管,mizoprostol和PGE2组之间的剖腹产率没有统计学上显著的差异 (29.1%对22.2%对23.0%).
- 在所有诱导方法 (10.6%,11.4%,6.9%) 中,产后出血率相似.
- 在肥胖女性中,福利导管安置失败率更高 (8.3%对3.2%) 和从福利转换方法的增加 (20.1%).
结论:
- 一个不显著的趋势表明,与肥胖妇女的口服mizoprostol相比,福利导管诱导的剖腹产增加.
- 这项研究缺乏足够的力量,无法在这个子组中得出最终的结论.
- 在肥胖女性中,福利导管安置失败的风险更高,应该为临床决策提供信息.
相关概念视频
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

